Effects of fremanezumab in patients with chronic migraine and comorbid depression: Subgroup analysis of the randomized HALO CM study.

ABSTRACT:

Objective

To evaluate the efficacy of fremanezumab in patients with chronic migraine (CM) and moderate to severe depression.

Background

Fremanezumab, a fully humanized monoclonal antibody that selectively targets calcitonin gene-related peptide, has been approved for the preventive treatment of migraine in adults. CM and depression are highly comorbid.

Methods

The 12-week, Phase 3 HALO trial randomized patients with CM to fremanezumab quarterly (675 mg/placebo/placebo), fremanezumab monthly (675/225/225 mg), or placebo. Post hoc analyses evaluated the effects of fremanezumab in patients with moderate to severe depression (baseline 9-item Patient Health Questionnaire sum score ≥10) on monthly number of headache days of at least moderate severity; monthly migraine days;

SUBMITTER: Lipton RB 

PROVIDER: S-EPMC8251795 | biostudies-literature | 2021 Apr

REPOSITORIES: biostudies-literature